secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2023-08-01T23:59:59+00:00
Accession:  0001193125-23-199907
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines to acquire EQRx in stock deal valued at ~$1.07B; pipeline updates and FY2023 guidance
--------------------------------------------------------------------------------

- Merger consideration: $200M fixed (7.69M shares) plus $870M based on pre-meeting VWAP with 6% discount; expected close Nov 2023.
- Voting agreements secured with >40% of EQRx shares and ~8% of RVMD shares to support the transaction.
- Company confirms FY2023 GAAP net loss guidance of $360M-$400M, inclusive of $40M-$50M stock-based compensation.
- Pipeline updates: RMC-6236 clinical data in NSCLC/pancreatic cancer expected Oct 2023; planning pivotal trials for 2024.
- Post-merger, company will not advance EQRx pipeline; EQRx programs to be wound down and IP returned to partners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000119312523199907/0001193125-23-199907-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000119312523199907/d534121d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-199907

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer